Phase 3 N=750 Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain
Postoperative Delirium · Postoperative Pain · Opioid Use
Primary: Incidence of Postoperative Delirium by Study Group — 84; 72 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=390 A Pivotal Study of a Facet Replacement System to Treat Spinal Stenosis
Lumbar Spinal Stenosis
Primary: Measure of Pain/Disability Using the Zurich Claudication Questionnaire (ZCQ) Physical Function Score — 1.7; 1.6; 1.7 score on a scale
Phase 4 N=777 ISCHEMIA-Chronic Kidney Disease Trial
Cardiovascular Diseases · Coronary Artery Disease · Heart Diseases
Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants
Phase 1 N=35 Tau Imaging in Professional Fighters
Alzheimer's Disease
Primary: Flortaucipir Imaging (Quantitative) Between Cognitive Groups — 1.0048; 0.971; 0.9731; 0.9357 standardized uptake value ratio (SUVr)
N/A N=51 Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
Phase 2 N=179 Clinical Evaluation of Flortaucipir F 18
Alzheimer's Disease · Traumatic Brain Injury · Depression
Primary: Number of Participants With Adverse Events Related to Flortaucipir Administration — 0; 3; 0; 3 Participants
Phase 2 N=34 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
Recurrent Bladder Urothelial Carcinoma · Recurrent Renal Pelvis Urothelial Carcinoma · Recurrent Ureter Urothelial Carcinoma
Primary: Response Rate — 8; 18 Participants
N/A N=50 Electric-Acoustic Stimulation Extended Follow-up Post Approval Study
Hearing Loss, Sensorineural
Primary: Percentage of Words Correct As Assessed by CUNY Sentence Test. — 61.33; 43.30 percentage of words correct
Phase 1 N=24 A Study of Olaratumab (LY3012207), Doxorubicin, and Ifosfamide in Participants With Advanced or Metastatic Soft Tissue Sarcoma
Soft Tissue Sarcoma
Primary: Number of Participants With Olaratumab Dose Limiting Toxicities (DLTs) — 4; 4 Participants
Phase 2 N=10 Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
Pharmacokinetics
Primary: Unbound Ceftolozane Exposure in the Plasma — 322.6 mg*h/L
N/A N=91 Clinical Evaluation of Multifocal Toric Contact Lenses
Visual Acuity
Primary: Overall Handling Comparison Between Test 1/Test 2 and Control — 57.1; 53.3; 52.3 units on a scale
Phase 2 N=284 Efficacy Of A PVP-I Fluoride Varnish
Dental Caries
Primary: Dental Caries for Primary Molars Sound at Baseline — 2.3; 3.3 units on a scale — p=0.037
N/A N=84 Comparison of Two Naloxone Infusion Rates on the Postoperative Recovery of Patients Undergoing Spine Fusion Surgery
Pain, Postoperative · Postoperative Nausea and Vomiting · Scoliosis
Primary: Number of Hours Until Tolerating Oral Intake — 25.9; 25.0 hours
N/A N=48 Feasibility Study to Evaluate Safety of ENvizion Medical™ ENVUE™ System
Enteral Nutrition
Primary: Number of Participants With Successfully Placed Enteral Feeding Tube — 43 Participants
N/A N=103 Percutaneous Less Invasive AV Fistula for Vascular Access in ESRD
End Stage Renal Disease · AV Fistula · Fistula
Primary: Maturation Success Rate at 90 Days — 92 Participants